# Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

> **NCT07137481** · PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 70 (estimated)

## Conditions studied

- Hematological Malignancies

## Interventions

- **DRUG:** C9/CD5CAR/IL-15 NK cells
- **DRUG:** Rituximab
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT07137481
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-02-28
- **Primary completion:** 2030-07-31
- **Final completion:** 2032-07-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07137481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07137481, "Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07137481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*